This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vinks, A. A.
Right arrow Articles by Mouton, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vinks, A. A.
Right arrow Articles by Mouton, J. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2003, p. 541-547, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.541-547.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Population Pharmacokinetic Analysis of Nonlinear Behavior of Piperacillin during Intermittent or Continuous Infusion in Patients with Cystic Fibrosis

Alexander A. Vinks,1* Jan G. den Hollander,2 Shelley E. Overbeek,3 Roger W. Jelliffe,4 and Johan W. Mouton2,5

Division of Pharmacology Research and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio,1 Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen,5 Department of Clinical Microbiology and Infectious Diseases,2 Department of Pulmonary Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands,3 Laboratory of Applied Pharmacokinetics, Keck School of Medicine, University of Southern California, Los Angeles, California4

Received 25 October 2001/ Returned for modification 12 August 2002/ Accepted 31 October 2002

The purpose of this study was to describe the nonlinear pharmacokinetics of piperacillin observed during intermittent infusion and continuous infusion by using a nonparametric population modeling approach. Data were 120 serum piperacillin concentration measurements from eight adult cystic fibrosis (CF) patients. Individual pharmacokinetic parameter estimates during intermittent infusion or continuous infusion were calculated by noncompartmental analysis and with a maximum iterative two-stage Bayesian estimator. To simultaneously describe concentration-time data during intermittent infusion and continuous infusion, nonlinear models were parameterized as two-compartment Michaelis-Menten models. Models were fit to the data with the nonparametric expectation maximization algorithm. The calculations were executed on a remote supercomputer. Nonlinear models were evaluated by log-likelihood estimates, residual plots, and R2 values, and predictive performance was based on bias (mean weighted error [MWE]) and precision (mean weighted square error [MWSE]). A linear pharmacokinetic model could not describe combined intermittent infusion and continuous infusion data well. A good population model fit to the intermittent infusion and continuous infusion data was obtained with the constructed nonlinear models. Maximum a posteriori probability (MAP) Bayesian R2 values for the nonlinear models were 0.96 to 0.97. Median parameter estimates for the best nonlinear model were as follows: Km, 58 ± 75 mg/liter (mean and standard deviation); Vmax, 1,904 ± 1,009 mg/h; volume of distribution of the central compartment, 14.1 ± 3.0 liters; k12, 0.63 ± 0.41 h-1; and k21, 0.37 ± 0.19 h-1. The median bias (MWE) and precision (MWSE) values for MAP Bayesian estimation with the Michaelis-Menten model were 0.05 and 4.6 mg/liters, respectively. The developed nonlinear pharmacokinetic models can be used to optimize piperacillin therapy administered via continuous infusion in patients with CF and have distinct advantages over conventional linear models.

* Corresponding author. Mailing address: Pharmacology Research Center, MLC 7025, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH 45229. Phone: (513) 636-0159. Fax: (513) 636-0168. E-mail: sander.vinks{at}chmcc.org.

Antimicrobial Agents and Chemotherapy, February 2003, p. 541-547, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.541-547.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Owens, R. C. Jr., Shorr, A. F. (2009). Rational dosing of antimicrobial agents: Pharmacokinetic and pharmacodynamic strategies. Am J Health Syst Pharm 66: S23-S30 [Abstract] [Full Text]  
  • Bulitta, J. B., Duffull, S. B., Kinzig-Schippers, M., Holzgrabe, U., Stephan, U., Drusano, G. L., Sorgel, F. (2007). Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers. Antimicrob. Agents Chemother. 51: 2497-2507 [Abstract] [Full Text]  
  • Gavin, P. J., Suseno, M. T., Thomson, R. B. Jr., Gaydos, J. M., Pierson, C. L., Halstead, D. C., Aslanzadeh, J., Brecher, S., Rotstein, C., Brossette, S. E., Peterson, L. R. (2006). Clinical Correlation of the CLSI Susceptibility Breakpoint for Piperacillin- Tazobactam against Extended-Spectrum-{beta}-Lactamase-Producing Escherichia coli and Klebsiella Species.. Antimicrob. Agents Chemother. 50: 2244-2247 [Abstract] [Full Text]  
  • Li, C., Kuti, J. L., Nightingale, C. H., Mansfield, D. L., Dana, A., Nicolau, D. P. (2005). Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 56: 388-395 [Abstract] [Full Text]  
  • Lodise, T. P. Jr., Lomaestro, B., Rodvold, K. A., Danziger, L. H., Drusano, G. L. (2004). Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation. Antimicrob. Agents Chemother. 48: 4718-4724 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»